These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 19728753)
1. Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer. Ondrusova M; Ondrus D; Dusek L; Spanikova B Neoplasma; 2009; 56(6):473-9. PubMed ID: 19728753 [TBL] [Abstract][Full Text] [Related]
2. Testosterone Deficiency and Bone Metabolism Damage in Testicular Cancer Survivors. Ondrusova M; Spanikova B; Sevcikova K; Ondrus D Am J Mens Health; 2018 May; 12(3):628-633. PubMed ID: 27489147 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin. Bandak M; Jørgensen N; Juul A; Lauritsen J; Kier MGG; Mortensen MS; Daugaard G Eur Urol Focus; 2018 Jul; 4(4):591-598. PubMed ID: 28753832 [TBL] [Abstract][Full Text] [Related]
4. Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of β-hCG and cancer treatment. Steggink LC; van Beek AP; Boer H; Meijer C; Lubberts S; Oosting SF; de Jong IJ; van Ginkel RJ; Lefrandt JD; Gietema JA; Nuver J Andrology; 2019 Jul; 7(4):441-448. PubMed ID: 30609309 [TBL] [Abstract][Full Text] [Related]
5. Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Brown JE; Ellis SP; Silcocks P; Blumsohn A; Gutcher SA; Radstone C; Hancock BW; Hatton MQ; Coleman RE Clin Cancer Res; 2006 Nov; 12(21):6480-6. PubMed ID: 17085662 [TBL] [Abstract][Full Text] [Related]
6. Altered bone status in unilateral testicular cancer survivors: Role of CYP2R1 and its luteinizing hormone-dependency. Foresta C; Selice R; De Toni L; Di Mambro A; Carraro U; Plebani M; Garolla A J Endocrinol Invest; 2013 Jun; 36(6):379-84. PubMed ID: 23047203 [TBL] [Abstract][Full Text] [Related]
7. Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors. Bandak M; Jørgensen N; Juul A; Lauritsen J; Oturai PS; Mortensen J; Hojman P; Helge JW; Daugaard G Eur J Cancer; 2017 Oct; 84():9-17. PubMed ID: 28772110 [TBL] [Abstract][Full Text] [Related]
8. Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction. Skøtt JW; Lauritsen J; Kreiberg M; Daugaard G; Bandak M Clin Genitourin Cancer; 2019 Feb; 17(1):e65-e71. PubMed ID: 30293923 [TBL] [Abstract][Full Text] [Related]
9. High prevalence of hypogonadism determined by serum free testosterone level in Japanese testicular cancer survivors. Kurobe M; Kawai K; Suetomi T; Iwamoto T; Waku N; Kawahara T; Kojima T; Joraku A; Miyazaki J; Nishiyama H Int J Urol; 2018 May; 25(5):457-462. PubMed ID: 29478250 [TBL] [Abstract][Full Text] [Related]
10. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. Nuver J; Smit AJ; Wolffenbuttel BH; Sluiter WJ; Hoekstra HJ; Sleijfer DT; Gietema JA J Clin Oncol; 2005 Jun; 23(16):3718-25. PubMed ID: 15738540 [TBL] [Abstract][Full Text] [Related]
11. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. Sprauten M; Brydøy M; Haugnes HS; Cvancarova M; Bjøro T; Bjerner J; Fosså SD; Oldenburg J J Clin Oncol; 2014 Feb; 32(6):571-8. PubMed ID: 24419125 [TBL] [Abstract][Full Text] [Related]
12. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Nord C; Bjøro T; Ellingsen D; Mykletun A; Dahl O; Klepp O; Bremnes RM; Wist E; Fosså SD Eur Urol; 2003 Sep; 44(3):322-8. PubMed ID: 12932930 [TBL] [Abstract][Full Text] [Related]
13. Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones. Aschim EL; Oldenburg J; Kristiansen W; Giwercman A; Witczak O; Fosså SD; Haugen TB Hum Reprod; 2014 Dec; 29(12):2844-51. PubMed ID: 25336703 [TBL] [Abstract][Full Text] [Related]
14. Dynamics of hormonal disorders following unilateral orchiectomy for a testicular tumor. Wiechno PJ; Kowalska M; Kucharz J; Sadowska M; Michalski W; Poniatowska G; Jońska-Gmyrek J; Rzymkowska J; Nietupski K; Demkow T Med Oncol; 2017 May; 34(5):84. PubMed ID: 28389909 [TBL] [Abstract][Full Text] [Related]
15. Hypogonadism risk in men treated for childhood cancer. Romerius P; Ståhl O; Moëll C; Relander T; Cavallin-Ståhl E; Wiebe T; Giwercman YL; Giwercman A J Clin Endocrinol Metab; 2009 Nov; 94(11):4180-6. PubMed ID: 19789207 [TBL] [Abstract][Full Text] [Related]
16. Vitamin D status among long-term survivors of testicular cancer. Schepisi G; De Padova S; Scarpi E; Lolli C; Gurioli G; Menna C; Burgio SL; Rossi L; Gallà V; Casadio V; Salvi S; Conteduca V; De Giorgi U Oncotarget; 2017 May; 8(22):36780-36786. PubMed ID: 28030821 [TBL] [Abstract][Full Text] [Related]
17. Hypogonadism and androgen deficiency symptoms in testicular cancer survivors. Lackner JE; Märk I; Schatzl G; Marberger M; Kratzik C Urology; 2007 Apr; 69(4):754-8. PubMed ID: 17445664 [TBL] [Abstract][Full Text] [Related]
18. Sexual Function and Quality of Life in a National Cohort of Survivors of Bilateral Testicular Cancer. Bandak M; Lauritsen J; Johansen C; Kreiberg M; Skøtt JW; Agerbaek M; Holm NV; Daugaard G Eur Urol Focus; 2020 Jul; 6(4):711-719. PubMed ID: 30482585 [TBL] [Abstract][Full Text] [Related]
19. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. Petersen PM; Skakkebaek NE; Vistisen K; Rørth M; Giwercman A J Clin Oncol; 1999 Mar; 17(3):941-7. PubMed ID: 10071288 [TBL] [Abstract][Full Text] [Related]
20. Treatment of testicular cancer: influence on pituitary-gonadal axis and sexual function. Lackner J; Schatzl G; Koller A; Mazal P; Waldhoer T; Marberger M; Kratzik C Urology; 2005 Aug; 66(2):402-6. PubMed ID: 16040104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]